Emerging Lung Cancer Vaccine

18 June 2014

Emerging Lung Cancer Vaccine Targets Tumor Blood Vessels – Introducing Vallovax We are raising funds to get FDA approval for our new lung cancer vaccine ValloVax. Animal data is promising and the vaccine appears to have no side effects. Read the full article at indiegogo.com [video_left][video_frame] [iframe url=”http://www.youtube.com/embed/IWUYR8fPc5U” width=”572″ height=”312″] [/video_frame]....

Read Full Article About Businesswire.com

Cancer’s Shield Against the Immune System?

9 June 2014

In this video, Samuel Wagner, President and CEO of Batu Biologics, discusses the significance of the tumor endothelium as the first immunological barrier masking the tumor from detection and destruction by the host’s immune system. [video_left][video_frame] [iframe url=”http://www.youtube.com/embed/1jukjsAEwJ8″ width=”572″ height=”312″] [/video_frame] Watch the video....

Read Full Article About Businesswire.com

Batu Biologics Announces FDA Development Plans for ValloVax™

8 June 2014

Batu Biologics Announces FDA Development Plans for ValloVax™ Angiogenesis-Targeting Cancer Vaccine Company Plans to Develop “Next Generation” Govallo Cancer Vaccine, VG-1000, for American Population Currently the strongest evidence points to Govallo’s Vaccine, termed VG-1000, as working through inhibiting production of new blood vessels in tumors. We are aggressively pursuing this hypothesis as an underlying theme … Continue reading "Batu Biologics Announces FDA Development Plans for ValloVax™"....

Read Full Article About Businesswire.com

Files Patent Covering its Proprietary Cancer Vaccine

23 May 2014

Batu Biologics Files Patent Covering its Proprietary Cancer Vaccine Targeting the Tumor Endothelium: Vallovax Animal Studies Demonstrate Efficacy in Treatment of Non-Small Cell Lung Cancer Angiogenesis has proven to be a key factor in the proliferation of tumor cells within the host. Recent studies have revealed that without the formation of new blood vessels, tumors … Continue reading "Files Patent Covering its Proprietary Cancer Vaccine"....

Read Full Article About Businesswire.com

Batu Biologics Authors Peer-Reviewed Publication

15 May 2014

Batu Biologics Authors Peer-Reviewed Publication on Intravenous Vitamin C as Adjuvant to Cancer Immunotherapy Integration of Holistic Approach to Cancer with Cutting Edge Immunotherapy Although Batu Biologics is highly focused on the clinical development of ValloVax, a cancer vaccine targeting tumor endothelium, from a corporate perspective we want to ensure that we have the highest … Continue reading "Batu Biologics Authors Peer-Reviewed Publication"....

Read Full Article About Businesswire.com

Batu Biologics Files Patent

9 May 2014

Batu Biologics Files Patent Covering New Use of Approved Drug for Decreasing Cancer Immunotherapy Toxicity Company Aims to Provide Platform Allowing for Overcoming Rate Limiting Toxicity of Immunotherapy Several years ago, the promise of immunotherapy was just a dream. Today, with the FDA approval of Provenge, the market entry of immunological checkpoint inhibitors, and the … Continue reading "Batu Biologics Files Patent"....

Read Full Article About Businesswire.com
1 4 5 6